In December 2019, a cluster of cases was diagnosed with unexplained pneumonia in Wuhan, of which the pathogen was soon isolated and identified as a novel coronavirus.[@bib1] The disease then spread to the whole world rapidly. Positive result of Reverse Transcription-Polymerase Chain Reaction (RT-PCR) for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in respiratory specimen was considered infectious and listed as one of diagnosis criteria of COVID-19.[@bib2] The case highlights that patient had a long duration of virus shedding for 46 days and the factors that may affect the natural duration of virus shedding.

Case report {#sec1}
===========

A 40-year-old man, who worked in Wuhan, presented to the outpatient of local hospital with a 12-days history of cough, a little white foamy sputum and shortness of breath ([Fig. 1](#fig1){ref-type="fig"} a) on January 16th,2020. The underlying diseases he had were chronic hepatitis B infection and diabetes. Chest CT ([Fig. 1](#fig1){ref-type="fig"}b) on January 12th,2020 had showed thickened lung texture, multiple patches of consolidation near the pleura. On admission, the patient received empiric drugs Meropenem/Levofloxacin and Oseltamivir. Then on January 18th, 2020, the result of first RT-PCR test performed on oropharyngeal swab was negative.Figure 1a) Timeline of symptoms and results of RT-PCR. b) The pre-treatment CT features of a COVID-19 case. The CT showed bilateral patchy ground-glass opacities and consolidation with air bronchogram on the January 12th, 2020. c)The post-treatment CT features of a COVID-19 case. The CT showed apparent absorption on January 26th,2020. Until the patient discharged from the hospital, the ground-glass lesions were not absorbed completely.Figure 1

Then the second RT-PCR test performed on the bronchoalveolar lavage fluid(BALF) firstly proved to be positive and the patient was diagnosed with COVID-19 officially. After doctors\' careful treatment, the patient\'s symptoms relieved and the CT scan ([Fig. 1](#fig1){ref-type="fig"}c) showed apparent absorption of bilateral lesions on January 26th. The treatment regimens included antiviral agents including Ribavirin, Interferon-α, Arbidol hydrochloride, Lopinavir/Ritonavir and Chloroquine and antibiotics like Moxifloxacin and Doxycycline without steroids.

Eventually, he was discharged from the hospital with a total hospitalized days of 35 days on February 22nd, 2020. And in all, the patient received RT-PCR test for 11 times and finally turned to be negative after 25 days of respiratory symptoms relief and obviously exudative lesions absorption on CT.

Discussion {#sec2}
==========

Our report illustrates that the SARS-CoV-2 RNA exist in patient\'s respiratory tract for 46 days from illness onset, which is the a really long period of virus shedding. A recent study reported the median duration of virus shedding is 20.0 days (IQR, 17.0--24.0) since the symptoms appear.[@bib3] 46 days is far longer than the known 37 days, which may completely subverted our knowledge of the time of virus shedding of acute respiratory viral infections.

Prolonged virus shedding of MERS-CoV had been observed in animal models of immunosuppression.[@bib4] As described, except for chronic hepatitis B infection and diabetes, the patient has no other history of immune dysfunction. Therefore, the reasons for prolonged virus shedding may be associated with complications. In a study about MERS-CoV, Hail M et al. find that diabetes was related to prolonged detection of respiratory MERS-CoV RNA.[@bib5] Moreover, Chronic hepatitis B infection can lead to immune cell dysfunction, which may partly explain virus shedding. Therefore, we highlight that the SARS-CoV-2 can present persistently in the patients combined with complications like diabetes and chronic hepatitis B infection, which deserved doctors' specially attention in the treatment of COVID-19.
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